## Ubaldo E Martinez-Outschoorn

## List of Publications by Year in Descending Order

 $\textbf{Source:} \ https://exaly.com/author-pdf/7891082/ubaldo-e-martinez-outschoorn-publications-by-year.pdf$ 

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56 papers

3,862 citations

34 h-index 57 g-index

57 ext. papers

4,675 ext. citations

avg, IF

5.59 L-index

#	Paper	IF	Citations
56	Cigarette Smoke Induces Metabolic Reprogramming of the Tumor Stroma in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 1893-1909	6.6	10
55	Monocarboxylate Transporter 4 (MCT4) Knockout Mice Have Attenuated 4NQO Induced Carcinogenesis; A Role for MCT4 in Driving Oral Squamous Cell Cancer. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 324	5.3	22
54	Fructose 2,6-Bisphosphate in Cancer Cell Metabolism. Frontiers in Oncology, 2018, 8, 331	5.3	46
53	Autophagy in cancer: a complex relationship. <i>Biochemical Journal</i> , <b>2018</b> , 475, 1939-1954	3.8	41
52	Metformin Effects on Metabolic Coupling and Tumor Growth in Oral Cavity Squamous Cell Carcinoma Coinjection Xenografts. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2018</b> , 158, 867-877	5.5	6
51	Metformin Clinical Trial in HPV+ and HPV- Head and Neck Squamous Cell Carcinoma: Impact on Cancer Cell Apoptosis and Immune Infiltrate. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 436	5.3	18
50	Metformin as a Therapeutic Target in Endometrial Cancers. Frontiers in Oncology, 2018, 8, 341	5.3	30
49	Cancer metabolism: a therapeutic perspective. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 11-31	19.4	659
48	EBV-associated Peripheral T-Cell Lymphoma of Gastrointestinal Tract Presented With Widespread Chronic Inflammation: A Case Report. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2017</b> , 25, e1-e8	1.9	1
47	Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 615-619	4.4	9
46	Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. <i>Laryngoscope</i> , <b>2017</b> , 127, 1808-1815	3.6	35
45	Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. <i>FASEB Journal</i> , <b>2017</b> , 31, 3412-3424	0.9	38
44	Tumor Metabolism in the Microenvironment of Nodal Metastasis in Oral Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, <b>2017</b> , 157, 798-807	5.5	9
43	Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. <i>Oncotarget</i> , <b>2017</b> , 8, 9868-9884	3.3	35
42	Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 1465-1467	4.4	1
41	Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma. <i>Seminars in Oncology</i> , <b>2017</b> , 44, 204-217	5.5	21
40	Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. <i>Seminars in Oncology</i> , <b>2017</b> , 44, 218-225	5.5	25

## (2014-2017)

39	Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer. <i>Seminars in Oncology</i> , <b>2017</b> , 44, 226-232	5.5	30
38	Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development. <i>Seminars in Oncology</i> , <b>2017</b> , 44, 198-203	5.5	141
37	TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 26291-26303	5.4	48
36	A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 141	<b>-<del>8</del></b> ∙7	21
35	Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 72395-72414	3.3	19
34	Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). <i>Aging</i> , <b>2016</b> , 8, 1593-607	5.6	83
33	Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. <i>Oncotarget</i> , <b>2016</b> , 7, 34084-99	3.3	127
32	Multicompartment metabolism in papillary thyroid cancer. <i>Laryngoscope</i> , <b>2016</b> , 126, 2410-2418	3.6	13
31	Cancer stem cell metabolism. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 55	8.3	261
30	A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 646-52	4.7	36
29	Caveolae and signalling in cancer. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 225-37	31.3	135
28	Metastasis and Oxidative Stress: Are Antioxidants a Metabolic Driver of Progression?. <i>Cell Metabolism</i> , <b>2015</b> , 22, 956-8	24.6	64
27	Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis. <i>BioMed Research International</i> , <b>2015</b> , 2015, 242437	3	56
26	Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic Correlates. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 909	-12/2	6
25	Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 915-22	5.5	24
24	Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. <i>Oncotarget</i> , <b>2015</b> , 6, 30453-71	3.3	84
23	Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. <i>Seminars in Cancer Biology</i> , <b>2014</b> , 25, 47-60	12.7	252
22	Metabolic asymmetry in cancer: a "balancing act" that promotes tumor growth. <i>Cancer Cell</i> , <b>2014</b> , 26, 5-7	24.3	15

21	Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. <i>Seminars in Oncology</i> , <b>2014</b> , 41, 195-216	5.5	141
20	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. <i>Cell Cycle</i> , <b>2014</b> , 13, 580-99	4.7	42
19	Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?. <i>Seminars in Oncology</i> , <b>2013</b> , 40, 403-18	5.5	35
18	Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFItompletely prevents breast cancer tumor formation in vivo. <i>Cell Cycle</i> , <b>2013</b> , 12, 480-90	4.7	23
17	Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. <i>Cell Cycle</i> , <b>2013</b> , 12, 1371-84	4.7	159
16	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. <i>Cell Cycle</i> , <b>2013</b> , 12, 818-25	4.7	42
15	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: implications for breast cancer prevention. <i>Cell Cycle</i> , <b>2013</b> , 12, 289-301	4.7	39
14	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. <i>Cell Cycle</i> , <b>2013</b> , 12, 2935-6	4.7	11
13	Compartment-specific activation of PPARIgoverns breast cancer tumor growth, via metabolic reprogramming and symbiosis. <i>Cell Cycle</i> , <b>2013</b> , 12, 1360-70	4.7	23
12	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFB target stromal MCT4. <i>Cell Cycle</i> , <b>2013</b> , 12, 2580-97	4.7	65
11	Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. <i>Cell Cycle</i> , <b>2013</b> , 12, 2723-32	4.7	90
10	Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. <i>Cell Cycle</i> , <b>2013</b> , 12, 172-82	4.7	64
9	Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. <i>Cell Cycle</i> , <b>2012</b> , 11, 4390-401	4.7	118
8	Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. <i>Cell Cycle</i> , <b>2012</b> , 11, 3956-63	4.7	89
7	The milk protein Easein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. <i>Cell Cycle</i> , <b>2012</b> , 11, 3972-82	4.7	23
6	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. <i>Cell Cycle</i> , <b>2012</b> , 11, 3599-610	4.7	147
5	Ketone body utilization drives tumor growth and metastasis. Cell Cycle, 2012, 11, 3964-71	4.7	113
4	Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1 and HIF2 in tumor-associated fibroblasts and human breast cancer cells. <i>Cell Cycle</i> , <b>2012</b> , 11, 3280-9	4.7	67

## LIST OF PUBLICATIONS

3	Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. <i>Cell Cycle</i> , <b>2012</b> , 11, 3403-14	4.7	37
2	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. <i>Cell Cycle</i> , <b>2012</b> , 11, 4402-13	4.7	64
1	Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFB activation in the tumor stroma. <i>Cell Cycle</i> , <b>2012</b> , 11, 4152-66	4.7	41